Method for distinguishing normal and transformed cells using G1 kinase inhibitors

Patent · Fri Jan 01 00:00:00 EST 1993

OSTI ID:868655

Crissman, Harry A ^[1]; Gadbois, Donna M ^[1]; Tobey, Robert A ^[1]; Bradbury, E Morton ^[2]

---

1. Los Alamos, NM
2. Santa Fe, NM

A G.sub.1 phase kinase inhibitor is applied in a low concentration to a population of normal and transformed mammalian cells. The concentration of G.sub.1 phase kinase inhibitor is selected to reversibly arrest normal mammalian cells in the G.sub.1 cell cycle without arresting growth of transformed cells. The transformed cells may then be selectively identified and/or cloned for research or diagnostic purposes. The transformed cells may also be selectively killed by therapeutic agents that do not affect normal cells in the G.sub.1 phase, suggesting that such G.sub.1 phase kinase inhibitors may form an effective adjuvant for use with chemotherapeutic agents in cancer therapy for optimizing the killing dose of chemotherapeutic agents while minimizing undesirable side effects on normal cells.

• Research Organization: Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
• DOE Contract Number: W-7405-ENG-36
• Assignee: United States of America as represented by United States (Washington, DC)
• Patent Number(s): US 5185260
• OSTI ID: 868655
• Country of Publication: United States
• Language: English

Related Subjects

method
distinguishing
normal
transformed
cells
g1
kinase
inhibitors
phase
inhibitor
applied
concentration
population
mammalian
selected
reversibly
arrest
cell
cycle
arresting
growth
selectively
identified
cloned
diagnostic
purposes
killed
therapeutic
agents
affect
suggesting
form
effective
adjuvant
chemotherapeutic
cancer
therapy
optimizing
killing
dose
minimizing
undesirable
effects
therapeutic agents
normal cells
cancer therapy
cell cycle
mammalian cells
therapeutic agent
phase kinase
diagnostic purposes
kinase inhibitor
/435/424/999/